DIUPRES-250 Drug Patent Profile

« Back to Dashboard

Which patents cover Diupres-250, and when can generic versions of Diupres-250 launch?

Diupres-250 is a drug marketed by Merck and is included in one NDA.

The generic ingredient in DIUPRES-250 is chlorothiazide; reserpine. Additional details are available on the chlorothiazide; reserpine profile page.

Summary for DIUPRES-250

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DIUPRES-250

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	DIUPRES-250	chlorothiazide; reserpine	TABLET;ORAL	011635-003	Aug 26, 1987		DISCN	No	No

Last updated: May 2, 2026

DIUPRES-250: What do the fundamentals imply for investment?

No complete, verifiable patent or regulatory ownership record is available for “DIUPRES-250” in the provided context. Without identifiers (active ingredient, dosage form, marketing authorization holder, application/approval numbers, or patent family links), a fundamentals and investment scenario analysis cannot be produced in a way that is accurate and decision-grade.

What is DIUPRES-250 (active, strength, dosage form) and who owns it?

No authoritative mapping from “DIUPRES-250” to:

• Active pharmaceutical ingredient (API)
• Dosage form (tablet, capsule, suspension, etc.)
• Marketing authorization holder (MAH)
• Regulatory application/approval identifiers is available in the provided context.

What is the IP position (key patents, expiration, and exclusivity)

No reliable patent family association for “DIUPRES-250” is available in the provided context, so the following cannot be established:

• Patent numbers and assignees
• Priority dates
• Claim scope and competitors’ workaround risk
• Patent term end (PT)
• Regulatory exclusivities (where applicable)
• Likelihood of generic entry timing

What is the market setup (indications, competition, reimbursement)

No indication set, target population, pricing/reimbursement status, or competitive landscape for “DIUPRES-250” is available in the provided context, so market fundamentals cannot be quantified.

Investment scenario framework

Because the product-to-asset identification is not established, any scenario built on fundamentals (revenue ramp, margins, generic erosion, litigation probability, tender or formulary outcomes) would be non-actionable.

Key Takeaways

• A decision-grade investment scenario for DIUPRES-250 requires a verified asset mapping to API and rights holders; that mapping is not present in the provided context.
• Without confirmed active ingredient and patent family links, IP-timing, generic-risk, and expected revenue erosion cannot be calculated.
• No investment conclusion can be produced without a verifiable product identity and associated regulatory and patent records.

FAQs

1. What makes a fundamentals analysis decision-grade for a drug asset?
   Verified API identity, regulatory identifiers, MAH/assignee mapping, and a linked patent family with dates and jurisdictions.

2. Can “drug name + strength” alone support IP and generic timing?
   No. Many products share similar naming conventions; accuracy depends on API and legal entity ownership.

3. What primary inputs drive the investment scenario for a branded drug?
   Patent expirations and exclusivities, litigation history, formulary status, pricing dynamics, and competitor entry schedules.

4. How does the generic “erosion schedule” get modeled in practice?
   By combining statutory exclusivity/patent expiry dates, ANDA/marketing authorizations status, launch dates, and observed uptake curves.

5. What is the minimum patent evidence needed to model downside risk?
   Patent family coverage (claims tied to the marketed product), grant status, priority dates, jurisdictional term calculations, and known challenge indicators.

References

[1] No cited sources available from the provided context.